Syndax Pharmaceuticals

SNDX

Market cap $1.23B

The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call trade candidates due to the liquidity and lucrativeness of the option premiums against these equities. Stocks had their biggest decline last Friday since the first half of April due to escalating trade tensions between the U.S. and China.

How to trade and invest in the biotech space, according to ROTY Biotech Community's Jonathan Faison. Favoring late-stage, commercial-stage companies with clear paths to profitability and strong sales ramp potential.

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2025 the Company granted inducement awards to purchase up to 138,900 shares of common stock to 10 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have good balance sheets. The article below discusses three promising names that have bright futures but also could attract interest from larger names in the industry.

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia were updated to include revumenib as a category 2A recommendation for relapsed or refractory (R/R) acute myeloid leukemia (AML) with an NPM1 mutation (mNPM1).1 The update was based on positive pivotal results from the AUGMENT-101 trial of revumenib which were published in the journal Blood in 2025. 2 The NCCN Guidelines for AML and acute lymphoblastic leukemia (ALL) continue to also include revumenib as a category 2A recommendation for R/R acute leukemia with a KMT2A rearrangement.

FDA approval of revumenib for r/r KMT2Ar AML patients drives strong revenue growth for Syndax Pharmaceuticals, with Q2 2025 sales up 43% quarter-over-quarter. Upcoming FDA Priority Review decision for sNDA in r/r mNPM1 AML offers a significant near-term catalyst, with a PDUFA date set for October 25, 2025. Expansion into metastatic MSS colorectal cancer represents a major pipeline opportunity, targeting a large market with data expected by the end of 2025.

NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025 the Company granted inducement awards to purchase up to 167,400 shares of common stock to 11 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Citi's Biopharma Back to School Conference September 2, 2025 4:45 PM EDT Company Participants Keith Goldan - CFO, Treasurer & Chief Accounting Officer Steven Closter - Chief Commercial Officer Nicholas Botwood - Head of Research & Development and Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst Welcome, everyone, to the, I believe, the last session of the first day of Citi's Biopharma Back-to-School Summit. I'm Yigal Nochomovitz, biotech analyst here at Citi.

The mean of analysts' price targets for Syndax (SNDX) points to an 112.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: